European Notebook: Greek Pharma Export Ban; Patient Engagement Cluster At EMA And FDA; Trade Talks
Executive Summary
Europe’s politicians been busy, alleviating economic meltdown in Greece, keeping the U.S.-EU free trade negotiations on track, and making health care policy plans for the second half of the year, including piloting new pricing strategies based on payment for outcomes.
You may also be interested in...
European Notebook: Drug Pricing Collaborations; Biosimilar Switching; Scientific Advice
Dutch and Belgian health agencies will undertake a pilot project next year on jointly negotiating prices with pharma companies.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.